Psychiatric Pharmacogenomic Testing : A Primer for Clinicians - 08/05/25

Résumé |
Pharmacogenomic (PGx) testing is an evidence-based strategy to optimize the selection and dosing of certain psychotropic medications. An individual’s genetics play a role in medication response through pharmacokinetic and pharmacodynamic mechanisms. The current evidence base of psychiatric PGx mainly focuses on the metabolism of psychotropics through the cytochrome P450 (CYP) system. PGx testing and decision support tools are not yet standardized, resulting in variations in interpretation and prescribing recommendations. Clinicians are encouraged to use PGx results as part of the clinical picture, in addition to the patient’s overall clinical profile, in determining a personalized treatment plan for their patients.
Le texte complet de cet article est disponible en PDF.Keywords : Pharmacogenomics, Pharmacogenetics, Psychiatry, Precision medicine, Mental health, Implementation
Plan
Vol 48 - N° 2
P. 257-264 - juin 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
